A Probiotic-Derived Oxydifficidin from Bacillus subtilis Y4 Combines Direct Antibacterial Activity and Immunomodulatory Effects Against Multidrug-Resistant Acinetobacter baumannii Infection
This study identifies oxydifficidin, a probiotic-derived metabolite from *Bacillus subtilis* Y4, as a promising therapeutic agent that combats multidrug-resistant *Acinetobacter baumannii* infections through direct membrane-disrupting antibacterial activity and immunomodulatory effects that reduce lung inflammation and bacterial burden in immunosuppressed mice.